{"entity":{"id":"actinium-pharmaceuticals","kind":"company","name":"Actinium Pharmaceuticals","aka":[],"tldr":"Actinium Pharmaceuticals attaches the alpha-emitting isotope actinium-225 to antibodies to treat acute myeloid leukaemia and, more recently, solid tumours such as prostate and lung cancer. It is a small listed company whose lead programme is approaching new clinical milestones.","summary":"Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), headquartered in New York, develops targeted radiotherapies based on actinium-225 antibody radioconjugates and holds proprietary Ac-225 manufacturing technology. The lead programme Actimab-A is a CD33-targeting, mutation-agnostic therapy for relapsed or refractory acute myeloid leukaemia, with patents extending to solid tumours via myeloid-derived suppressor cells; the company expects clinical milestones from the fourth quarter of 2026. ATNM-400 is a first-in-class Ac-225 pan-tumour radiotherapy in preclinical development for metastatic castration-resistant prostate cancer, non-small cell lung cancer and breast cancer, with 2026 SNMMI data in androgen receptor inhibitor-resistant prostate models and KRAS and EGFR mutant lung models. Iomab-ACT is a targeted conditioning programme. In 2026 the company received NYSE American listing standards notices and appointed Steffen Heeger as Chief Medical Officer.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.actiniumpharma.com/"},{"label":"August 2026 Actimab-A and listing update","url":"https://ir.actiniumpharma.com/press-releases/detail/525/actinium-pharmaceuticals-announces-actimab-a-intellectual"},{"label":"Press releases","url":"https://ir.actiniumpharma.com/press-releases"}],"tags":[],"related":["ac-225"],"indications":["prostate"],"sections":[],"technologies":["radioimmunotherapy","targeted-alpha-therapy"],"targets":[],"drugs":["iomab-b"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Ticker, exchange and HQ confirmed via SEC EDGAR submissions data (CIK 0001388320). Public company; no private rounds listed. Founding year not sourced."],"hq":"New York, NY","country":"US","companyType":"radiopharma","website":"https://www.actiniumpharma.com/","ticker":"ATNM","stage":"public","investors":[],"funding":[]},"route":"/companies/actinium-pharmaceuticals/","neighbours":{"isotope":[{"id":"ac-225","kind":"isotope","name":"Actinium-225","route":"/isotopes/ac-225/"}],"indication":[{"id":"prostate","kind":"indication","name":"Prostate cancer","route":"/indications/prostate/"}],"technology":[{"id":"radioimmunotherapy","kind":"technology","name":"Radio-antibody & radio-ADC","route":"/technologies/radioimmunotherapy/"},{"id":"targeted-alpha-therapy","kind":"technology","name":"Targeted alpha therapy","route":"/technologies/targeted-alpha-therapy/"}],"drug":[{"id":"iomab-b","kind":"drug","name":"Iomab-B","route":"/drugs/iomab-b/"}],"trial":[{"id":"nct02665065","kind":"trial","name":"Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia","route":"/trials/nct02665065/"}],"bottleneck":[{"id":"b-ac225-supply","kind":"bottleneck","name":"Actinium-225 supply","route":"/bottlenecks/b-ac225-supply/"}],"section":[{"id":"f-alpha-therapy","kind":"section","name":"Targeted alpha therapy","route":"/fronts/f-alpha-therapy/"}]}}